Rapid detection of point mutations in genomic DNA has been achieved by chemical mismatch analysis of heteroduplexes formed between amplified wild-type and target sequences in the human factor EX gene. Amplification and mismatch detection (AMD) analysis of DNA from relatives of haemophilia B patients permitted carrier diagnosis by direct identification of the presence or absence of the mutation in all cases, thus eliminating the need for the informative segregation of polymorphic markers. This extends diagnostic capability to virtually all haemophilia B families. AMD analysis permits detection of all sequence variations in genomic DNA and is therefore applicable to direct diagnosis of X-1 inked and autosomal diseases and for identification of new polymorphisms for genetic mapping.
INTRODUCTION
The rapid and efficient detection of point mutations directly in genomic DNA is essential to identify polymorphisms for genetic studies, to determine the molecular basis of inherited diseases, and to provide carrier and prenatal diagnosis for genetic counselling. Diagnosis of haemophilia B at the DNA level to date has relied on the familial segregation of linked restriction fragment length polymorphisms (RFLPs) (1, 2) . This approach is successful in 65 % of all Caucasian cases, but fails in the remainder where the segregation of the marker is uninformative either because there is no family history (isolated cases: 15% of the total) or because of homozygosity in key family members (20% of the total) (1) . A further disadvantage of the use of linked markers for diagnosis is the requirement for DNA samples from selected relatives and often paternity testing. There is also the risk of misdiagnosis as a result of recombination between the marker and the mutation. This risk is minimal when intragenic RFLPs are used, but becomes significant for even very tightly linked extragenic markers. This is illustrated by one example in this study (see Results) . All these problems can be overcome by the direct detection of the causative mutation in each case.
Mutations causing haemophilia B are highly heterogeneous and unrelated patients are expected to carry independent mutations (1, 3) . Direct diagnosis must therefore be able to assay all the essential regions of the factor IX gene (see figure 1 ). Previously we have done this by direct sequencing of all the factor IX exons, plus intron-exon boundaries, promoter and termination signal regions amplified by PCR (4) . A faster procedure is required to eliminate extensive sequence analysis and thus to extend the direct detection of mutations to large populations or to larger genes. Several methods have been developed to detect point mutations and larger sequence changes. These have, however, lacked either the ability to detect all possible mutations or the sensitivity to analyse human genomic DNA. RNase RNA probes and genomic DNA detects only 60-70% of all possible point mutations (5) . Denaturing gradient gel electrophoresis (DGGE) (6) is also sufficiently sensitive to be applied to genomic DNA, but as no cleavage occurs at the mismatch site, the positional information obtained is imprecise (7) . Furthermore, in order to detect all mutations, the region of the mismatch must be flanked by at least one domain of higher melting temperature (either naturally occurring or incorporated as a G-C clamp) (8, 9) . Chemical modification of mismatched thymine or guanine residues with carbodiimide provides a method of detecting mutations by reduced mobility of modified DNA in gels (10); but as with DGGE, no cleavage occurs at the mismatch site. The use of hydroxylamine and osmium tetroxide to modify mispaired cytosines and thymines, respectively, followed by piperidine-catalysed cleavage of the modified heteroduplexes (11 -13) permits detection and localisation of all point mutations. However, neither of the above chemical procedures was applied directly to genomic DNA.
Amplification of target DNA sequences by the polymerase chain reaction (PCR) (14) prior to analysis solves the problem of sensitivity in detection of sequence variations in genomic DNA. We have used amplification and mismatch detection (AMD) analysis with hydroxylamine and osmium tetroxide modification to identify new mutations in the factor IX gene. We determine the carrier status of individuals which could not be identified using the previously established indirect methods. As AMD analysis can detect all point mutations and larger sequence variations in genomic DNA, it will be effective for carrier, pre-and postnatal diagnosis of virtually all cases of haemophilia B. It will also be applicable to the study of all types of mutations in other diseases, and to the detection of all sequence polymorphisms.
METHODS

Genomic DNA samples
Eleven haemophilia B patients and 12 of their relatives have been examined in this study. All patients are severe haemophiliacs except London 13. Four have known mutations: they are London 3, 4 and 5 (crm+) and London 8 (crm-) (4). Genomic DNA was isolated from blood samples by established techniques (15) . DNA amplification 50-100 ng of genomic DNA isolated from blood samples were used in the polymerase chain reaction (14) . The following conditions were used: 60 sec denaturation at 93°C; 30sec annealing at 55-58°C; 90 sec polymerisation at 72°C for 30 cycles using a reaction b) Domain structure of unprocessed factor IX polypeptide, and positions of mutations referred to in the text. The domains from the N-terminus are as follows: PRE: signal peptide; PRO: propeptide region (PRE and PRO are removed during maturation); GLA: region contains 12 carboxylated glutamic acid (gla) residues and binds via Ca + + to phospholipid surfaces; H: a short hydrophobic domain; EGF-TYPE B and TYPE A: epidermal growth factor (EGF)-like domains. The type B domain has a high affinity Ca + + -binding site and /3-hydroxylated aspartate 64 (29, 30) ; ACTIVATION: the activation domain, containing the 35 residue peptide that is removed during zymogen activation by either factor XI or factor VII plus tissue factor; CATALYTIC: the serine protease domain, which contains the active site residues His 221, Asp 269 and Ser 365; and also Asp 359 of the substrate binding pocket (31) .
Mutations referred to in the text are marked below the diagram: numbers in brackets refer to the amino acid which is affected by the mutation. buffer of 67mM Tris-HCl, pH 8.8, 16.6mM ammonium sulphate, 6.7mM magnesium chloride, lOmM (3-mercaptoethanol, 170 mg/ml bovine serum albumin, 0.5mM dNTPs, 300 ng of each primer, 50-100 ng DNA and 2.5-5 units of Taq polymerase (Cetus). Ten percent of the reaction products were analysed on a 1 % agarose minigel (Sigma, type V). The remainder was purified using Geneclean (Bio 101) and eluted in a final volume 20-50 ng of this were labelled with a-32 P-dCTP and a-32 P-dTTP by a fill-in reaction using the Klenow fragment of DNA polymerase 1. The probe was either used directly or purified by elution from a native 4% polyacrylamide gel.
The labelled probe (approximately 10 ng) was mixed with a 5-10-fold molar excess of amplified target DNA ( 50-100 ng) in 0.3M sodium chloride, 0.1M Tris-HCl pH 8, sealed in glass capillaries, boiled for 5 minutes then incubated at 65 °C for 6hrs or overnight. After hybridisation the samples were ethanol-precipitated with 30 ng mussel glycogen (BCL) and resuspended in lOmM Tris-HCl pH 8.0, 0.1 mM EDTA. Hydroxylamine modification (11, 13) : a fresh 4M solution of hydroxylamine hydrochloride (Aldrich) was made in water and titrated to pH 6 by addition of approximately 0.3 volumes of diethylamine (Aldrich). Heteroduplex DNA in 7 /il was incubated with 20 /tl of the hydroxylamine solution (2.3M final, approximately) at 37°C for 2 hr. Osmium tetroxide modification (11, 12) : a2% solution of osmium tetroxide (Aldrich, stored at 4°C) was made in water. Heteroduplex DNA in 9 fi\ was incubated with a premix containing 5mM Tris-HCl, pH 8, 0.5mM EDTA, 3% pyridine and 0.025% osmium tetroxide in a total volume of 25 /tl, at 37°C for 2 hr. Piperidine cleavage (17): after modification, the heteroduplexes were ethanol-precipitated, resuspended in 50 \i\ of a fresh 1M solution of piperidine (AJdrich) by vortexing for 30-60 sec and incubated at 90°C for 30 min. Samples were then ethanol-precipitated, resuspended in formamide dyes (deionised formamide, 0.1 % xylene cyanol and 0.1 % bromophenol blue) and electrophoresed on denaturing 6 or 8% polyacrylamide gels. Gels were exposed from 3 hr to overnight using preflashed X-Omat S film (Kodak). Sequence analysis: one-tenth of the PCR product was sequenced using the standard dideoxy sequencing protocol (18) 
RESULTS
Regions containing coding regions of the factor EX gene from wild-type and patient genomic DNA were amplified by PCR. The amplified sequences contained Sail restriction sites at both ends incorporated from the primers. Sail-cut wild-type samples were end-labelled to generate probes and mixed with a 5 -10-fold molar excess of the corresponding amplified patient DNA, the mixture was denatured by boiling, and reannealed. In the event of a sequence difference between the two samples, four products were formed: two heteroduplexes containing mismatched sequences, plus two homoduplexes (see example in figure 2). The annealed duplexes were modified with either hydroxylamine or osmium tetroxide, treated with piperidine to cleave DNA at all sites of modification, and the products were analysed. The use of a probe sequence labelled at both ends permitted simultaneous analysis of both heteroduplexes in the mixture. Thus one C-specific and one T-specific reaction were sufficient to detect all types of single base substitutions as every point mutation results in an unpaired cytosine or thymine in one of the labelled strands.
The method was tested using known haemophilia B mutations. Patient London 3 has a G to A substitution at position 6365 in exon b of the factor IX gene (see sequence in fig. 2 ). Hydroxylamine treatment of mismatched duplexes containing exon b resulted in the appearance of a 152 nt band representing the cleavage product, plus a 551 nt band representing uncleaved duplexes (fig 3a, lane 1) . Patient London 4 is another example of the same mutation, and similar results were obtained (fig 3b, lane 1) . In patient London 8, there is a T to C change at position 31117 in exon h. The two heteroduplexes formed are therefore (i) 5 3^SCA*|' and (ii) 3 ?. ' ; §TACA-y ( tne asterisks denote position of 32 P label). Analysis using osmium tetroxide resulted in the appearance of a 312 nt band representing the cleavage product of heteroduplex (i) as well as the uncleaved material at 715 nt (fig 3c, lane 1). In addition, a 398 nt band was seen. This is the correct size for the cleaved product of heteroduplex (ii), and is presumed to result from cleavage at the T residue that is immediately adjacent to the mismatched base itself. The C-A mismatch in heteroduplex (ii) presumably disrupts the structure of the adjacent A-T base pair. The ability of the method to detect single base substitutions led us to search for new mutations directly by AMD analysis. Exons b, c and h of seven haemophilia B patients were analysed using hydroxylamine (fig 4) . The band across all tracks in fig 4a is found  in the unmodified probe (fig 5a, lane 5) and is a reproducible artefact. Analysis of a known mutation (London 5) with a G to A point mutation at position 31119 was also included in lane 8; the expected band was seen at 392 nt. Three new mutations were identified. The mutations identified in London 13 and 14 and Malmo 7 were confirmed by direct sequencing. London 13 has a G to A transition at position 30992 in exon h which results in the amino acid change AJa 291 to Thr 291, and London 14 has a C to T transition at position 6460 in exon b which alters the codon for Arg 29 to the stop codon TGA. The change found in Malmo 7 is a C to T transition at position 30892 and will be discussed elsewhere (Montandon et al., in preparation). These mutations would account exactly for the sizes of the bands observed in the mismatch analysis.
Carrier diagnoses by chemical mismatch detection
Our AMD procedure detects mutations in heterozygotes and is thus applicable to carrier diagnosis for genetic counselling. We have studied, therefore, families of either isolated patients or of individuals uninformative for the intragenic markers.
London 3 (fig 3a) is an isolated case and RFLP analysis could not exclude carrier status in his sister. AMD analysis showed that the mutation is not present in the patient's mother (lane 2), and London 3 is therefore a new mutation. The patient's sister also (as expected) does not carry the mutation (lane 3). London 4 (fig 3b) is another isolated case and carries the same mutation as London 3. London 4 and London 3 are shown to have mutations of independent origin by these results. The mother of London 4 was shown to be a carrier by the appearance of the 152 nt band in lane 2, while his sister proved normal (lane 3). In fact London 4 was previously expected to be a new mutation because he has inherited the same polymorphic marker as his unaffected brother at the DXS 99 site, where his mother is heterozygous. DXS 99 was reported to be very tightly linked to the factor IX gene (19) , but our direct diagnosis demonstrates a recombination between the two sites. London 8 (fig 3c) is a familial case. The patient's grandmother and mother were obligatory carriers. AMD analysis detected the mutation in these two individuals and one of the aunts (fig 3c, lanes 2, 4 and 3 respectively) , thus demonstrating that the latter is also a carrier, while the younger aunt (fig 3c, lane 5) is not. London 13 is an isolated case and RFLP analysis could not exclude carrier status in his sister. AMD analysis showed that the mother (fig 5b, lane 2) was a carrier but the sister was not (fig 5b, lane 3) . London 14 is another isolated case whose mother has no informative RFLP markers. In this case the 301 nt mismatch band was apparent in both the mother and the sister (fig 5a, lanes 3 and 4  respectively) , indicating that they both carry the same nucleotide change as the patient. The band that runs across all tracks is also evident in the unmodified probe (fig 5a, lane  5) , and is therefore an artefact. 
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Bovine Protein C Table 1 . The amino acid change in Factor IX London 13 is denoted by the arrow. Boxed and encircled residues are negatively and positively charged, respectively. Source of data: human factor IX: (16, 28) ; bovine factor IX: (32); human factor X: (33); bovine factor X: (34); human prothrombin: (35); bovine prothrombin: (36); human factor VII: (37); human protein C: (38) ; bovine protein C: (39) .
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DISCUSSION
Hydroxylamine hydrochlonde and osmium tetroxide react specifically with pyrimidine bases in DNA. Hydroxylamine at pH 6 modifies the C5 = C6 double bond in cytosine which then labilises the ring to internal rearrangement and cleavage (20) . Osmium tetroxide modification is a thymine-specific reaction in which the C5=C6 double bond is oxidised (21, 22) . Double-stranded DNA is attacked very slowly, while single-stranded regions are readily modified. At the mismatch site, the secondary structure of the DNA is disrupted and it appears single-stranded, therefore being susceptible to rapid modification. Cotton et al. (13) reported the use of these chemicals to detect single base changes in plasmids and M13 clones containing the cytochrome P450 steroid 21 hydroxylase gene. Internally or end-labelled single-stranded probes were gel-purified and used with either chemical to detect possible mutations. This, however, does not determine the site and type of mutation with absolute certainty as it does not distinguish single base substitutions from deletions or insertions, and modification can extend to bases adjacent to the site of mismatch (see patient London 8 above). Therefore sequence analysis is required for complete characterisation. By applying the mismatch method to amplified DNA we have detected mutations at the genomic level. Using double-stranded probes with each strand labelled at the 3' end, both strands of the DNA are screened for mutations simultaneously. This halves the number of reactions required to detect all possible mutations. We have characterised each new mutation fully by direct sequencing. All the cases studied here are point mutations but larger mutations have also been detected (a 1 nt deletion in London 12; a 2 nt deletion in London 11; a 3 nt deletion in London 10 and an 8 nt deletion in Malmo 1-results not shown). The method is therefore likely to be effective for the identification of any sequence variation. The mutation identified in patient London 13 causes the amino acid change Ala 291 to Thr 291. This patient has mild haemophilia. Two assays of factor IX clotting activity in different laboratories gave results of 4% and 16%. This indicates the presence of at least some factor IX polypeptide in the blood, although the factor IX antigen levels were not measured. Amino acid 291 is a proline residue in clotting factors VII, X, prothrombin (see alignment in table 1) and all other serine proteases studied except factor IX. The high degree of conservation of both this residue and the charge arrangement on the adjacent residues 30-32 (see table 1) indicates that this region is likely to be important for serine protease structure and/or function. Thus alteration of residue 291 to a threonine in London 13 may be responsible for the marked (84-96%) reduction in either stability or activity of factor IX. In the absence of mismatch or sequence information on some of the remaining essential regions of the factor IX gene we cannot formally exclude the possibility that there is another mutation in this patient capable of causing mild haemophilia. If this were the case, it would not alter the exclusion of carrier status in the patient's sister but the maternal DNA would have to be tested for the presence of the second sequence change.
Patient London 14 has a stop codon (TGA) in place of the codon for Arg 29. This mutation would account for the severe haemophilia B that is observed (< 1% clotting activity). It has previously been observed that marked loss of factor IX coding information by either gene deletion (23) or formation of premature termination codons (4) is usually (80% of cases) associated with the inhibitor complication, i.e. the development of inhibiting antibodies to administered factor IX, in keeping with the proposal that mutations in this class predispose to the condition (24). Patient London 14 may be at risk of developing the inhibitor phenotype, as he has an identical mutation to the Swedish inhibitor patient, Malmo 4 (4). Alternatively, other genetic or environmental factors may prevent this complication in patient London 14, in common with patient London 11 (4), Seattle 2 (25) and the deletions reported by Wadelius et al. (26) .
Diagnosis by direct detection of mutations eliminates the need for informative segregation of linked markers, DNA samples from relatives of the individuals other than those requiring diagnosis, paternity testing and other pedigree information. It also eliminates the risk of recombination between the marker and the mutation. Thus in the case of London 4, a recombination was detected between the RFLP at the DXS 99 site and the mutation. DXS 99 is reported to be very tightly linked to factor IX (LOD score 9.79 at recombination fraction = 0) in the families studied by Mulligan et al. (19) . This is the third reported example of recombination between the factor IX gene and this marker, and indicates the need for caution in diagnostic conclusions based solely on this RFLP. AMD analysis permits accurate carrier and prenatal diagnosis in virtually all cases. The only residual problem is the determination of the carrier status of the mothers of isolated patients. Certainty in this case demands that the sequence change observed in the patient truly represents the detrimental mutation. This will be unequivocally established in many cases because of the nature of the mutation (e.g.: stop codons, frameshifts, alteration of essential features of the factor IX gene). In addition, if the origin of the change can be identified in the generations immediately preceding the affected individual, it is almost certain to be the detrimental mutation.
The speed with which AMD analysis identifies all possible sequence variations in genomic DNA makes the analysis of all mutations feasible in autosomal or X-linked diseases due to cloned genes, whatever their size and complexity. Furthermore, any polymorphic sequence variation can be detected and used as a genetic marker. Since the frequency of nucleotide changes in non-coding regions is expected to be of the order of 1 in 300 (autosomes) or 1 in 1100 (X chromosome) (27) , this approach is likely to detect informative polymorphisms in any given region of the genome.
